Newly issued share equity in Alvogen US acquired by Aztiq Pharma Partners
Aztiq Pharma Partners, a private equity fund led by Róbert Wessman, today announced that it has completed a US$100 million financing to purchase a newly issued share equity in Alvogen US. Morgan Stanley led the financing, which was subscribed by international institutional investors.
The capital was used by Aztiq to buy a 17% stake in Alvogen US, at Fora pre-money valuation of US$ 350 million.
Lisa Graver, President Alvogen USA
The new equity will allow Alvogen's generic business and its branded division Almatica Pharma to increase the R&D investment and expand branded sales channels in the US market
Almatica Pharma was established by Alvogen in 2017. Almatica is focused on the development, production, and marketing of novel treatments for serious central nervous system (CNS) diseases. Almatica's mission is to meaningfully improve the lives of patients around the world, by bringing to market a portfolio of novel CNS therapeutics.
Prior to today's share issue, Alvogen US was 100% owned by Alvogen Lux Holdings. Following Aztiq Pharma Partners' acquisition of these newly issued shares, Aztiq Pharma Partners holds a combined direct and indirect, approximate 40% stake in Alvogen US.
Róbert Wessman, CEO
Alvogen US is a very exciting investment opportunity. Many pipeline products are coming to the market in the next two years. Aztiq's vision is to increase patient access to the best medicines and to improve people's lives. With Aztiq's new investment in Alvogen US, the company can accelerate the growth of its R&D and sales & marketing platform in the US market
Aztiq Pharma Partners is a long-term investment fund focused on pharmaceuticals. Its mission is to improve patients’ lives better by increasing access to affordable high-quality medicines. Aztiq’s shareholder base consists of individual investors, led by Róbert Wessman, as well as major international investment funds.